Offer An Article

Pandemic Latest News

intellectual property

IP and breakthrough infections: Global Health Today

This is the third in a series of newsletters, offering the expert insight of Lalita Panicker – consulting editor, views, Hindustan Times, New Delhi – into some of the most pressing health issues of the day. This edition highlights vaccines – specifically, the IP debate and so-called breakthrough infections. To read the first, click here. COVID-19 […]

IP and breakthrough infections: Global Health Today Read More »

Intellectual property in the era of COVID-19

Much of the conversation surrounding the COVID-19 pandemic in recent months has focused on access to vaccines – specifically, vaccine accesses in low- and middle-income countries. But to what extent is re-examining intellectual property (IP) rights part of the solution?  As Health Issues India reported in May, “patent waivers for COVID-19 vaccines have been offered

Intellectual property in the era of COVID-19 Read More »

How the University of California is fighting proxy patent battle for expensive cancer drug in India

The following is taken from an article originally published in The Wire. It has been reprinted here with permission from the author. The original can be accessed here. New Delhi: Xtandi is a life-prolonging cancer drug and sells at about Rs 2.7 lakh for a month’s course in India – that’s for four tablets daily. It

How the University of California is fighting proxy patent battle for expensive cancer drug in India Read More »

Bucking the trend: Is India’s drug market back on the up?

“Bucking the trend” India’s drug market is starting to show signs of improvement after a rough few months, with everything from demonetisation to Donald Trump taking its toll. However, the future remains very much unclear. Demonetisation The Indian pharmaceutical market (IPM) is “bucking the trend of a sequential decline” according to MoneyControl, growing 9.6 percent

Bucking the trend: Is India’s drug market back on the up? Read More »

Trump’s triumph emboldens Indian pharma experts

The unexpected victory of Donald Trump in the U.S. presidential election has sent shockwaves reverberating throughout the world – but it has been suggested by some that his win is good news for Indian drugmakers. The President elect’s rhetoric on the campaign trail was often inflammatory and controversial. It included blaming India and China for

Trump’s triumph emboldens Indian pharma experts Read More »

India plans 15 more compulsory licences, says New York Times

An unnamed source has told the New York Times that an Indian committee is to recommend 15 more compulsory licences for medicines that the committee considers of public health importance but to be too expensive in India. That, at least, is how we read the article on the 29th of December by Gardiner Harris, the

India plans 15 more compulsory licences, says New York Times Read More »

Indian compulsory licence demands spreading from #pharma to #greenenergy – #patent

There is a long and complicated tussle over patents in the pharma sector in India. Over the past year, India has issued two compulsory licences for pharmaceuticals and made a number of other moves seen as hostile to patent holders (see this recent article on our , Health Issues India which gives a rundown) Now, according to Business

Indian compulsory licence demands spreading from #pharma to #greenenergy – #patent Read More »

India delights in US discomfort over #patents and impact on #accesstomedicines

There is widespread delight over last week’s decision by President Obama to veto a patent ruling that would have disadvantaged Apple and favoured Samsung. The ruling would have stopped Apple from selling some older iPhones in the USA on the grounds that they infringed Samsung’s patents. The US based its decision to over-rule the International Trade

India delights in US discomfort over #patents and impact on #accesstomedicines Read More »